ENOX1-AS2: A Potential Drug Target and Biomarker (G100874130)

Target Name: ENOX1-AS2

NCBI ID: G100874130

ENOX1-AS2

Other Name(s): ENOX1 antisense RNA 2

ENOX1-AS2: A Potential Drug Target and Biomarker

ENOX1-AS2, also known as CSF-1, is a cell surface glycoprotein that is expressed in various tissues and cell types, including neural cells, endothelial cells, and epithelial cells. ENOX1-AS2 has been shown to play a role in various physiological processes, including cell signaling, migration, and invasion. In addition, ENOX1-AS2 has also been implicated in the development and progression of various diseases, including cancer. As a result, targeting ENOX1-AS2 has become an attractive research topic in the field of molecular medicine.

Drug Targeting Strategies

One of the most effective strategies for targeting ENOX1-AS2 is the use of small interfering RNA (siRNA). SiRNA is a non-coding RNA molecule that can be designed to specifically target a specific mRNA molecule. By introducing a siRNA into ENOX1-AS2 cells, researchers can reduce the amount of ENOX1-AS2 protein produced and potentially disrupt its functions.

Another potential strategy for targeting ENOX1-AS2 is the use of antibodies. Antibodies are proteins that are designed to recognize a specific protein molecule and can be used to block its functions. By using antibodies against ENOX1-AS2, researchers can potentially reduce its expression or disrupt its functions.

Biomarker Development

ENOX1-AS2 has also been used as a potential biomarker for various diseases, including cancer. By measuring the level of ENOX1-AS2 in tissues or fluids, researchers can potentially monitor the progression of disease or the effectiveness of a treatment. For example, studies have shown that ENOX1-AS2 levels can be used as a biomarker for cancer, with higher levels of ENOX1-AS2 often being associated with the development of certain types of cancer.

Targeting ENOX1-AS2

Targeting ENOX1-AS2 is still an attractive research topic, and various studies have shown that it can be effective in disrupting its functions and improving the health of individuals.

One potential approach for targeting ENOX1-AS2 is the use of small interfering RNA (siRNA). By introducing a siRNA into ENOX1-AS2 cells, researchers have shown that they can reduce the amount of ENOX1-AS2 protein produced and potentially disrupt its functions.

Another potential approach for targeting ENOX1-AS2 is the use of antibodies. By using antibodies against ENOX1-AS2, researchers have shown that they can potentially reduce its expression or disrupt its functions.

Conclusion

ENOX1-AS2 is a cell surface glycoprotein that has been shown to play a role in various physiological processes and has also been implicated in the development and progression of various diseases. As a result, targeting ENOX1-AS2 has become an attractive research topic in the field of molecular medicine. By using various strategies, such as siRNA and antibodies, researchers have shown that they can potentially disrupt ENOX1-AS2's functions and improve the health of individuals. Further research is needed to fully understand the potential of ENOX1-AS2 as a drug target and biomarker.

Protein Name: ENOX1 Antisense RNA 2

The "ENOX1-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENOX1-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets